share_log

Merit Medical Systems' (NASDAQ:MMSI) Five-year Earnings Growth Trails the 6.4% YoY Shareholder Returns

Merit Medical Systems' (NASDAQ:MMSI) Five-year Earnings Growth Trails the 6.4% YoY Shareholder Returns

Merit Medical Systems(納斯達克股票代碼:MMSI)的五年收益增長落後於6.4%的股東回報率
Simply Wall St ·  04/25 02:36

The main point of investing for the long term is to make money. Furthermore, you'd generally like to see the share price rise faster than the market. Unfortunately for shareholders, while the Merit Medical Systems, Inc. (NASDAQ:MMSI) share price is up 36% in the last five years, that's less than the market return. The last year has been disappointing, with the stock price down 4.5% in that time.

長期投資的要點是賺錢。此外,您通常希望看到股價的上漲速度快於市場。對於股東來說,不幸的是,儘管Merit Medical Systems, Inc.(納斯達克股票代碼:MMSI)的股價在過去五年中上漲了36%,但仍低於市場回報率。去年令人失望,當時股價下跌了4.5%。

Since the stock has added US$155m to its market cap in the past week alone, let's see if underlying performance has been driving long-term returns.

由於該股僅在過去一週的市值就增加了1.55億美元,因此讓我們看看基礎表現是否推動了長期回報。

While markets are a powerful pricing mechanism, share prices reflect investor sentiment, not just underlying business performance. By comparing earnings per share (EPS) and share price changes over time, we can get a feel for how investor attitudes to a company have morphed over time.

雖然市場是一種強大的定價機制,但股價反映了投資者的情緒,而不僅僅是潛在的業務表現。通過比較每股收益(EPS)和一段時間內的股價變化,我們可以了解投資者對公司的態度是如何隨着時間的推移而變化的。

During the five years of share price growth, Merit Medical Systems moved from a loss to profitability. That would generally be considered a positive, so we'd hope to see the share price to rise.

在股價增長的五年中,Merit Medical Systems從虧損轉爲盈利。這通常被認爲是積極的,因此我們希望看到股價上漲。

The company's earnings per share (over time) is depicted in the image below (click to see the exact numbers).

該公司的每股收益(隨着時間的推移)如下圖所示(點擊查看確切數字)。

earnings-per-share-growth
NasdaqGS:MMSI Earnings Per Share Growth April 24th 2024
納斯達克GS:2024年4月24日MMSI每股收益增長

We know that Merit Medical Systems has improved its bottom line over the last three years, but what does the future have in store? Take a more thorough look at Merit Medical Systems' financial health with this free report on its balance sheet.

我們知道Merit Medical Systems在過去三年中提高了利潤,但是未來會發生什麼?通過這份免費的資產負債表報告,更全面地了解Merit Medical Systems的財務狀況。

A Different Perspective

不同的視角

Merit Medical Systems shareholders are down 4.5% for the year, but the market itself is up 27%. Even the share prices of good stocks drop sometimes, but we want to see improvements in the fundamental metrics of a business, before getting too interested. On the bright side, long term shareholders have made money, with a gain of 6% per year over half a decade. It could be that the recent sell-off is an opportunity, so it may be worth checking the fundamental data for signs of a long term growth trend. It's always interesting to track share price performance over the longer term. But to understand Merit Medical Systems better, we need to consider many other factors. For example, we've discovered 1 warning sign for Merit Medical Systems that you should be aware of before investing here.

Merit Medical Systems的股東今年下跌了4.5%,但市場本身上漲了27%。即使是優質股票的股價有時也會下跌,但我們希望在過於感興趣之前看到企業基本指標的改善。好的一面是,長期股東賺了錢,在過去的五年中,每年增長6%。最近的拋售可能是一個機會,因此可能值得查看基本面數據以尋找長期增長趨勢的跡象。長期跟蹤股價表現總是很有意思的。但是,爲了更好地了解Merit Medical Systems,我們需要考慮許多其他因素。例如,我們發現了Merit Medical Systems的1個警告信號,在投資這裏之前,你應該注意這個信號。

If you are like me, then you will not want to miss this free list of growing companies that insiders are buying.

如果你像我一樣,那麼你不會想錯過這份業內人士正在收購的成長型公司的免費名單。

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges.

請注意,本文引用的市場回報反映了目前在美國交易所交易的股票的市場加權平均回報。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論